You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1336 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Jul 2024
Drug
Other Name(s): Xeloda®
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Neoadjuvant
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024

Pages